Background: Bimatoprost ophthalmic solution 0.03% was approved in the US for reducing intraoccular pressure (IOP) based on two double-masked, active-controlled clinical trials. Four additional long-term studies ($12 months) were conducted; however, the aggregate safety profile of the six studies has not been reported. Methods: Adverse events (AEs) were pooled from six double-masked, active-controlled, long-term clinical trials in which subjects received bimatoprost 0.03% once daily (QD) or twice daily (BID) as an eyedrop. AE terms were converted to MedDRA (V.11.0) Preferred Terms and analyzed. Results: In total, 1409 patients received more than one dose of bimatoprost 0.03% QD or BID. Most AEs were mild in severity and reported by 86.7% (QD) and 94.8% (BID) of subjects (#12 months of treatment). AEs reported through month 12 (aggregate incidence of $5%) were conjunctival hyperemia, increased eyelash growth, eye pruritus, periocular skin hyperpigmen-tation, eye irritation, dry eye, and hypertrichosis. AE onset was generally reported within four months of treatment. The cumulative incidence of common AEs in the QD treatment group at 24-48 months was similar to that measured at 12 months of treatment. Conclusion: Bimatoprost 0.03% has a favorable safety and tolerability profile as characterized by six long-term studies. Common AEs were due to the known pharmacological activity of bimatoprost and reversible with treatment cessation. © 2011 Wirta et al, publisher and licensee Dove Medical Press Ltd.
CITATION STYLE
Wirta, D., van Denburgh, A. M., Weng, E., Whitcup, S. M., Kurstjens, S., & Beddingfield, F. C. (2011). Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: A pooled analysis of six double-masked, randomized, active-controlled clinical trials. Clinical Ophthalmology, 5(1), 759–765. https://doi.org/10.2147/OPTH.S17457
Mendeley helps you to discover research relevant for your work.